Icosavax highlights anticipated milestones for 2023

Icosavax provided a corporate update and highlighted anticipated milestones for 2023. "We enter 2023 energized by the recent six-month immunogenicity data from our IVX-121 Phase 1/1b study, which we believe provides the first clinical evidence of potential differentiation on durability using Icosavax’s VLP platform technology," said Adam Simpson, Chief Executive Officer of Icosavax. "With the Phase 1 trial of IVX-A12 — our differentiated, bivalent vaccine combination of IVX-121 for RSV and IVX-241 for hMPV — on track to report topline results in mid-2023, and with our plans to initiate a Phase 2 study of IVX-A12 in the second half of the year, I believe we are poised to make further strides towards our vision of creating pan-respiratory vaccines for older adults." Near-Term Milestone Expectations: IVX-121 Phase 1b extension, 12-month immunogenicity data expected in mid-2023; IVX-A12 Phase 1 topline interim data expected in mid-2023; IVX-A12 Phase 2 initiation expected in 2H 2023; Flu program candidate selection expected in 2023; COVID-19 bivalent candidate selection expected in 2023.